
Hamidreza Montazeri Aliabadi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6373551/publications.pdf Version: 2024-02-01



Hamidreza Montazeri

#	Article	IF	CITATIONS
1	[(WR)8WKβA]-Doxorubicin Conjugate: A Delivery System to Overcome Multi-Drug Resistance against Doxorubicin. Cells, 2022, 11, 301.	4.1	8
2	Redox-Responsive Disulfide Cyclic Peptides: A New Strategy for siRNA Delivery. Molecular Pharmaceutics, 2022, 19, 1338-1355.	4.6	6
3	Combinational silencing of components involved in JAK/STAT signaling pathway. European Journal of Pharmaceutical Sciences, 2022, 175, 106233.	4.0	4
4	Suppression of Human Coronavirus 229E Infection in Lung Fibroblast Cells via RNA Interference. Frontiers in Nanotechnology, 2021, 3, .	4.8	4
5	Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity. European Journal of Medicinal Chemistry, 2021, 226, 113836.	5.5	14
6	Peptide/Lipid-Associated Nucleic Acids (PLANAs) as a Multicomponent siRNA Delivery System. Molecular Pharmaceutics, 2021, 18, 986-1002.	4.6	11
7	A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies. Acta Biomaterialia, 2020, 102, 351-366.	8.3	17
8	Prospects for RNAi Therapy of COVID-19. Frontiers in Bioengineering and Biotechnology, 2020, 8, 916.	4.1	69
9	Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs. Frontiers in Oncology, 2019, 9, 1070.	2.8	9
10	Amphiphilic Peptides for Efficient siRNA Delivery. Polymers, 2019, 11, 703.	4.5	19
11	Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research. Expert Opinion on Drug Delivery, 2018, 15, 397-418.	5.0	23
12	Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells. Acta Biomaterialia, 2018, 66, 294-309.	8.3	31
13	In vitro and ex-vivo evaluation of topical formulations designed to minimize transdermal absorption of Vitamin K1. PLoS ONE, 2018, 13, e0204531.	2.5	4
14	"Do We Know Jack―About JAK? A Closer Look at JAK/STAT Signaling Pathway. Frontiers in Oncology, 2018, 8, 287.	2.8	283
15	Difatty Acyl-Conjugated Linear and Cyclic Peptides for siRNA Delivery. ACS Omega, 2017, 2, 6939-6957.	3.5	10
16	Tumor-targeted delivery of siRNA using fatty acyl-CGKRK peptide conjugates. Scientific Reports, 2017, 7, 6093.	3.3	20
17	Alzheimer's Disease: Dawn of a New Era?. Journal of Pharmacy and Pharmaceutical Sciences, 2017, 20, 184.	2.1	13
18	ldentification of Potential Drug Targets in Cancer Signaling Pathways using Stochastic Logical Models. Scientific Reports, 2016, 6, 23078.	3.3	24

#	Article	IF	CITATIONS
19	Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells. Journal of Biomedical Materials Research - Part A, 2016, 104, 3031-3044.	4.0	20
20	Single and Combinational siRNA Therapy of Cancer Cells: Probing Changes in Targeted and Nontargeted Mediators after siRNA Treatment. Molecular Pharmaceutics, 2016, 13, 4116-4128.	4.6	17
21	Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines. Frontiers in Bioengineering and Biotechnology, 2015, 3, 14.	4.1	21
22	Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy. Pharmaceutical Research, 2015, 32, 3813-3826.	3.5	14
23	Effective downâ€regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipidâ€substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy. Journal of Biomedical Materials Research - Part A, 2014, 102, 3216-3228.	4.0	22
24	Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy. Journal of Controlled Release, 2013, 172, 219-228.	9.9	56
25	Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy. Journal of Biomedical Materials Research - Part A, 2013, 102, n/a-n/a.	4.0	13
26	Effective down-regulation of Breast Cancer Resistance Protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 33-42.	4.3	33
27	Induction of Apoptosis by Survivin Silencing through siRNA Delivery in a Human Breast Cancer Cell Line. Molecular Pharmaceutics, 2011, 8, 1821-1830.	4.6	61
28	The Immunosuppressive Activity of Polymeric Micellar Formulation of Cyclosporine A: In Vitro and In Vivo Studies. AAPS Journal, 2011, 13, 159-168.	4.4	16
29	Impact of Lipid Substitution on Assembly and Delivery of siRNA by Cationic Polymers. Macromolecular Bioscience, 2011, 11, 662-672.	4.1	77
30	Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution. Biomaterials, 2005, 26, 7251-7259.	11.4	123